Corcept Therapeutics Reports Q1 2026 Financial Results with $164.9M Revenue and $31.8M Net Loss

Corcept Therapeutics Incorporated reported its financial results for the first quarter of 2026, revealing a net product revenue of $164.9 million, an increase of 4.3% from $157.2 million in the same period of 2025. This growth was primarily driven by a 12.4% increase in sales volume, although it was partially offset by a 6.7% decrease in average selling price due to higher sales from the recently launched authorized generic version of Korlym. The company incurred a net loss of $31.8 million, compared to a net income of $20.5 million in the prior year, reflecting a significant shift in profitability.

Operating expenses surged to $214.5 million for the quarter, up from $153.8 million in the previous year, largely due to increased selling, general, and administrative expenses, which rose to $145.4 million from $90.7 million. Research and development expenses also increased to $66.3 million, driven by advancements in various development programs. The company’s total liabilities decreased to $176.9 million from $188.8 million at the end of 2025, while total stockholders' equity fell to $638.0 million from $647.8 million.

In terms of strategic developments, Corcept received FDA approval for Lifyorli™ (relacorilant) in March 2026, which is now being marketed for the treatment of platinum-resistant ovarian cancer. The company began selling Lifyorli in April 2026, marking a significant addition to its product portfolio. Additionally, Corcept has committed to purchasing $10.2 million worth of active pharmaceutical ingredients to ensure sufficient supply for its products, including Korlym and its authorized generic version.

Operationally, Corcept's cash and cash equivalents stood at $108.7 million as of March 31, 2026, down from $120.5 million at the end of 2025. The company reported a net cash used in operating activities of $16.8 million for the quarter, a stark contrast to the $4.8 million generated in the same period last year. The decrease in cash flow was attributed to the net loss and higher operating expenses. Corcept's employee headcount remained stable, with no significant changes reported.

Looking ahead, Corcept anticipates that its research and development expenses will continue to rise as it advances its clinical programs and initiates new trials. The company expects to fund its operations and planned activities over the next 12 months without the need for additional financing, although it may consider raising funds for strategic reasons. The ongoing development of its product pipeline, including relacorilant and other selective cortisol modulators, remains a key focus as the company aims to expand its market presence and address unmet medical needs.